

Immunoglobulin E in health and disease

M. Amarasekera*

Department of Physiology, Faculty of Medicine, University of Kelaniya, Ragama 11010, Sri Lanka

The discovery of immunoglobulin E (IgE) was a breakthrough in the field of Allergy and Immunology. Our understanding of mechanisms of allergic reactions and the role of IgE in these disorders has paralleled to the discovery of treatment modalities for patients with allergy. Apart from allergic diseases, IgE is involved in pathogenesis of other disorders. Much controversy exists about the control of total IgE (tIgE) levels and allergen-specific IgE (sIgE) profiles in allergic individuals. This review aims at giving a comprehensive overview of IgE molecule and discussing the issues related to its importance in clinical setting.

Key words: Immunoglobulin E; Allergy

Basic characteristics of immunoglobulin E (IgE)

The discovery of IgE was made much later than the discovery of other immunoglobulin subclasses. The first clue to the existence of a substance responsible for hypersensitivity reactions was demonstrated in 1921 by Prausnitz and Kustner, and after only four decades (1967) it was identified as an immunoglobulin subclass by Ishizakas and co-workers [1]. In 1968, The WHO International Reference Centre for Immunoglobulins announced the presence of a fifth immunoglobulin isotype, IgE [2]. IgE is the antibody isotype that contains the ϵ heavy chain and it is a monomer with five domains in the immunoglobulin structure. It is normally present in plasma at a concentration of less than 1 $\mu\text{g/mL}$ and has a half-life of about 2 days in serum [3]. A new unit (kU/L or IU/mL) was introduced to express the level of IgE in peripheral blood to alleviate the inconvenience in expressing the very low levels of serum IgE. One kU/L is equal to 2.4 ng/mL [4].

Once produced, IgE binds to its receptor Fc ϵ R, which are of two main types. High-affinity receptors (Fc ϵ RI) are found on wide variety of cells; mast cells, basophils, antigen presenting cells, monocytes and platelets [5-7] whereas low-affinity receptors (Fc ϵ RII) are found to be expressed on B-cells [7], monocytes [8] and dendritic cells [9]. The role of high affinity receptors in the pathogenesis of allergy is well understood [2, 7] but the biological role of low-affinity receptors is still unclear.

The role of IgE in health and disease

IgE was discovered for its involvement in allergic reactions (Type I hypersensitivities). People, who have a tendency to develop symptoms when exposed to allergens, produce IgE specific to that allergen, which evokes a cascade of reactions [10]. In terms of evolution, it is highly unlikely that IgE evolved to contribute to the pathology of allergy, hence people started

Correspondence: M. Amarasekera
Department of Physiology, Faculty of Medicine, University of Kelaniya, Ragama 11010, Sri Lanka
Tel: +94-714143184
Fax: +94-112958337
E-mail: manori_a@yahoo.com

Received: November 18, 2010
Accepted: November 28, 2010

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

investigating the exact role of IgE in human. It has been shown that the dominant role of IgE is to protect the host from parasitic infections, specially helminth infections [11]. Hence it is believed that IgE has evolved to protect the human from helminth infections, which once was the major threat for the survival of the human species [12, 13].

Role of IgE in helminth infections

IgE plays a vital role in the cross-talk between innate and adaptive immunity. Helminths are large parasites that can not be engulfed by phagocytes and could be best dealt by cytotoxic cells. Invasion of tissues by helminths stimulates an immune response which generates a cytokine milieu that shifts the TH₀ cells to mature along the TH₂ pathway. These TH₂ cells secrete interleukin (IL) 4 which induces the B cells to switch the immunoglobulin class to IgE. At the same time secreted IL 5 enhances the production and maturation of eosinophils [14].

IgE molecules coat the parasite which enables the tissue mast cells and circulating eosinophils to bind via their IgE receptors. This interaction of IgE with their receptors initiates a cascade of reactions in these cells which results in release of histamine and other toxic substances to the exterior [15]. Eosinophils that are recruited to the site of infection release granule proteins such as major basic protein, eosinophil cationic protein. These toxic substance released from the cells in the vicinity of the invading parasite are capable of killing the parasite [16, 17].

IgE in allergic reactions

Understanding the role of IgE in allergic reaction has been a major breakthrough in the field of allergy. It has paved the way for the discovery of effective drugs for these diseases. The sequence of events in the allergic reaction consists of the production of IgE antibodies in response to an allergen, binding of IgE to Fc receptors of mast cells, cross-linking of the bound IgE by the allergen upon re-exposure, and release of mast cell mediators such as histamine, lipid mediators and cytokines. Some mast cell mediators cause rapid increase in vascular permeability and smooth muscle contraction, resulting in many of the symptoms [18, 19].

The above reaction does not take place in every individual when exposed to environmental allergens. People with a genetic predisposition, called atopics, have a personal tendency to develop IgE when exposed to otherwise harmless environmental allergens. Such individuals have allergen-specific IgE (sIgE) in their serum reflecting their exposure to allergens in the past [10].

Levels of total IgE (tIgE) and sIgE

The rising trend of allergic diseases in the affluent populations in developed countries was alarming [19]. Investigations were carried out to find markers of allergy in such populations. The observation of high levels of tIgE in allergic individuals compared to healthy controls lead to identifying a cut-off level of tIgE for a diagnosis of allergy. It was observed that the probability is very high in predicting allergy when the tIgE level is above 200 kU/L [20, 21]. Longitudinal studies have demonstrated that levels of IgE increases with age from birth, regardless of atopic status but the increment in atopic children is abrupt and continue to have high levels in adult hood [22, 23]. Since most somatic IgE is bound by its receptors, serum IgE may not necessarily reflect the systemic IgE levels. However, Dehlink and co-workers have been able to demonstrate that the level of serum IgE correlates well with cell-bound IgE [24]. Nevertheless, a high tIgE level alone is of limited value as a marker of allergy as it does not give any clue to sensitizing allergens in an individual. Hence, attention was paid more on sIgE as a biomarker.

The pool of IgE in an individual is the sum of IgE produced against different allergens - ie: specific IgE. Presence of sIgE in serum indicates that the individual has been exposed to the allergen earlier (sensitized). Presence of sIgE against a particular allergen above a level of 0.35 kU_A/L is deemed positive for that allergen [10]. A person is said to be atopic if laboratory data shows a positive test. It should be noted that a positive result does not always correlate well with the clinical feature of a person. People with positive test for a particular allergen may not necessarily get symptoms when exposed to that allergen [25, 26]. Although, a positive test (a level \geq 0.35 kU_A/L) for aeroallergens generally correlates well with the clinical expression, much controversy exists for food allergens [27, 28, 29]. The difficulty in defining a single reference value for all the food allergens has made doctors uncomfortable in interpreting reports. Different reference values for different food allergens have been suggested based on clinical evidence, but this makes the clinicians life extremely complicated when managing patients. Thus, well conducted cross-sectional and longitudinal studies are needed to reach a consensus in this regard.

IgE levels in populations in tropics

Recently, there had been much interest on how the allergic response is modulated by helminths in people living in helminth endemic areas of the tropics. Serum levels of tIgE are very high in such people despite being non-atopic [13, 30]. Indeed, it is observed that the tIgE levels are several folds higher in them

compared to atopic people in the developed western countries emphasizing the limited use of tIgE as a marker of allergy in tropics [13]. It is known that helminths are capable of inducing IgE synthesis markedly [30]. Analysis of IgE molecules in such people has revealed that most of these IgE are non-specific [31, 32]. It is postulated that polyclonal synthesis of IgE is a mechanism of the parasite to evade the host immune response against it [32]. The mechanism of immune evasion by helminths is not well elucidated to date. The observation of high tIgE and low sIgE levels in populations in tropics is interesting and needs to be explored since it reflects some of the facts related to the control of IgE synthesis.

Lynch et al have reported that helminths enhance the polyclonal synthesis of IgE resulting in high tIgE levels, while down-regulating the production of sIgE [32]. This suggests that control of tIgE and sIgE is independent from each other. Direct evidence for this comes from the study done by Sunyer and colleagues, which showed that tIgE levels are associated with asthma even in subjects negative for sIgE to common aeroallergens [33]. It should be noted that the population for the latter study comes from an area not endemic for helminth infections. Reinforcing this notion, genetic studies have revealed different genetic loci for tIgE levels and sIgE profiles [34-36]

Elevated tIgE in other diseases

The presence of high levels of tIgE in allergic diseases is well documented. Nevertheless, there are other situations where an increase in the level is observed. Hyper IgE syndrome, IgE myeloma, some disorders of vasculitis, though rare, should be considered in differential diagnosis for extremely high tIgE levels [37].

Therapeutic implications

The cornerstone of an allergic reaction is the cross-linking of IgE molecules bound to mast cell receptors. Neutralization of IgE antibodies is a conceptually new approach for the treatment of allergic diseases. Recombinant monoclonal humanized anti-IgE has demonstrated promising results as a treatment for asthma in adults [38]. Further studies are needed to evaluate long-term safety and efficacy in the treatment of allergic diseases with anti-IgE treatment in children [39].

References

- Galli Lantz CS. Allergy. In: Paul WE, editor. *Fundamenta immunology*. 4th ed. Philadelphia: Lippincott- Raven; 1999. p. 1127-9.
- Bennich HH, Ishizaka K, Johansson SGO, Rowe DS, Stanworth DR, Terry WD. Immunoglobulin E, a new class of human immunoglobulin. *Bull World Health Organ* 1968;38:151-2.
- Abbas AK, Lichtman AH. *Basic immunology functions and disorders of the immune system*. 2nd ed. Philadelphia: Saunders; 2004.
- Seagroatt V, Anderson SG. The second international reference preparation for human serum immunoglobulin E and the first British standard for human serum immunoglobulin E. *J Biol Stand* 1981;9:431-7.
- Kraft S, Kinet JP. New developments in FcεRI regulation, function and inhibition. *Nat Rev Immunol* 2007;7:365-78.
- Kubota T, Mukai K, Minegishi Y, Karasuyama H. Different stabilities of the structurally related receptors for IgE and IgG on the cell surface are determined by length of the stalk region in their α-chains. *J Immunol* 2006;176:7008-14.
- Gould HJ, Sutton BJ. IgE in allergy and asthma today. *Nat Rev Immunol* 2008;8:205-17.
- Saini SS, Klion AD, Holland SM, Hamilton RG, Bochner BS, MacGlashan DW Jr. The relationship between serum IgE and surface levels of FcεRI on human leukocytes in various diseases: correlation of expression with FcεRI on basophils but not on monocytes or eosinophils. *J Allergy Clin Immunol* 2000;106:514-20.
- Bieber T. Fc εRII/CD23 on epidermal Langerhans' cells. *Res Immunol* 1992;143:445-7.
- Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. *J Allergy Clin Immunol* 2004;113:832-6.
- Snow RE, Chapman CJ, Holgate ST, Stevenson FK. Immunogenetics of human IgE. *Hum Antibodies Hybridomas* 1996;7:157-66.
- Ledin A, Arnemo JM, Liberg O, Hellman L. High plasma IgE levels within the Scandinavian wolf population, and its implications for mammalian IgE homeostasis. *Mol Immunol* 2008;45:1976-80.
- Levin ME, Le Souëf PN, Motala C. Total IgE in urban Black South African teenagers: the influence of atopy and helminth infection. *Pediatr Allergy Immunol* 2008;19:449-54.
- Finkelman FD, Urban JF Jr. The other side of the coin: the protective role of the T_H2 cytokines. *J Allergy Clin Immunol* 2001;107:772-80.
- Hagan P. IgE and protective immunity to helminth infections. *Parasite Immunol* 1993;15:1-4.
- Hamann KJ, Gleich GJ, Checkel JL, Loegering DA, McCall JW, Barker RL. In vitro killing of microfilariae of *Brugia pahangi* and *Brugia malayi* by eosinophil granule proteins. *J Immunol* 1990;144:3166-73.
- Gleich GJ, Ottesen EA, Leiferman KM, Ackerman SJ. Eosinophils and human disease. *Int Arch Allergy Appl Immunol* 1989;88:59-62.
- Kay AB. Allergy and allergic diseases. First of two parts. *N Engl J Med* 2001; 344:30-7.
- Holgate ST. The epidemic of allergy and asthma. *Nature* 1999;402 (6760 Suppl):B2-4.
- Carosso A, Bugiani M, Migliore E, Antò JM, DeMarco R. Reference

- values of total serum IgE and their significance in the diagnosis of allergy in young European adults. *Int Arch Allergy Immunol* 2007;142:230-8.
21. Wittig HJ, Belloit J, De Fillippi I, Royal G. Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. *J Allergy Clin Immunol* 1980;66:305-13.
 22. Sherrill DL, Stein R, Halonen M, Holberg CJ, Wright A, Martinez FD. Total serum IgE and its association with asthma symptoms and allergic sensitization among children. *J Allergy Clin Immunol* 1999;104:28-36.
 23. Nickl R, Illi S, Lau S, Sommerfeld C, Bergmann R, Kamin W, Forster J, Schuster A, Niggemann B, Wahn U. Variability of total serum immunoglobulin E levels from birth to the age of 10 years. A prospective evaluation in a large birth cohort (German Multicenter Allergy Study). *Clin Exp Allergy* 2005;35:619-23.
 24. Dehlink E, Baker AH, Yen E, Nurko S, Fiebiger E. Relationships between levels of serum IgE, cell-bound IgE, and IgE-receptors on peripheral blood cells in a pediatric population. *PLoS One* 2010;5:e12204.
 25. Wickman M. When allergies complicate allergies. *Allergy* 2005;60 Suppl 79:14-8.
 26. Pastorello EA, Incorvaia C, Ortolani C, Bonini S, Canonica GW, Romagnani S, Tursi A, Zanussi C. Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergens. *J Allergy Clin Immunol* 1995;96:580-7.
 27. Miceli Sopo S, Radzik D, Calvani M. The predictive value of specific immunoglobulin E levels for the first diagnosis of cow's milk allergy. A critical analysis of pediatric literature. *Pediatr Allergy Immunol* 2007;18:575-82.
 28. Komata T, Söderström L, Borres MP, Tachimoto H, Ebisawa M. Usefulness of wheat and soybean specific IgE antibody titers for the diagnosis of food allergy. *Allergol Int* 2009;58:599-603.
 29. Wainstein BK, Yee A, Jelley D, Ziegler M, Ziegler JB. Combining skin prick, immediate skin application and specific-IgE testing in the diagnosis of peanut allergy in children. *Pediatr Allergy Immunol* 2007;18:231-9.
 30. Cooper PJ, Alexander N, Moncayo AL, Benitez SM, Chico ME, Vaca MG, Griffin GE. Environmental determinants of total IgE among school children living in the rural Tropics: importance of geohelminth infections and effect of anthelmintic treatment. *BMC Immunol* 2008;9:33.
 31. Hagel I, Lynch NR, Pérez M, Di Prisco MC, López R, Rojas E. Modulation of the allergic reactivity of slum children by helminthic infection. *Parasite Immunol* 1993;15:311-5.
 32. Lynch NR, Hagel IA, Palenque ME, Di Prisco MC, Escudero JE, Corao LA, Sandia JA, Ferreira LJ, Botto C, Perez M, Le Souef PN. Relationship between helminthic infection and IgE response in atopic and nonatopic children in a tropical environment. *J Allergy Clin Immunol* 1998;101:217-21.
 33. Sunyer J, Antó JM, Castellsagué J, Soriano JB, Roca J. Total serum IgE is associated with asthma independently of specific IgE levels. The Spanish Group of the European Study of Asthma. *Eur Respir J* 1996;9:1880-4.
 34. Graves PE, Kabesch M, Halonen M, Holberg CJ, Baldini M, Fritzsche C, Weiland SK, Erickson RP, von Mutius E, Martinez FD. A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. *J Allergy Clin Immunol* 2000;105:506-13.
 35. Marsh DG, Neely JD, Breazeale DR, Ghosh B, Freidhoff LR, Ehrlich-Kautzky E, Schou C, Krishnaswamy G, Beaty TH. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. *Science* 1994;264:1152-6.
 36. Mansur AH, Bishop DT, Markham AF, Morton NE, Holgate ST, Morrison JF. Suggestive evidence for genetic linkage between IgE phenotypes and chromosome 14q markers. *Am J Respir Crit Care Med* 1999;159:1796-802.
 37. Nowicka U. Disorders with elevated immunoglobulin E levels. *Pneumonol Alergol Pol* 2009;77:533-40.
 38. Milgrom H. Anti-IgE therapy in allergic disease. *Curr Opin Pediatr* 2004;16:642-7.
 39. D'Amato G, Piccolo A, Salzillo A, Noschese P, D'Amato M, Liccardi G. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma. *Recent Pat Inflamm Allergy Drug Discov* 2007;1:225-31.